Open Collections

UBC Faculty Research and Publications

Biologic and Small Molecule Therapy in Atopic Dermatitis Shergill, Mahek; Bajwa, Barinder; Yilmaz, Orhan; Tailor, Karishma; Bouadi, Naila; Mukovozov, Ilya

Abstract

Atopic dermatitis is a chronic inflammatory dermatosis characterized by pruritic, scaly, erythematous lesions. Its incidence varies but is estimated to be approximately 20% in children and between 7 and 14% in adults, with variation amongst countries. It is a multifactorial condition, with a complex interplay between genetic, immunological, and environmental factors. Research into the inflammatory response has identified new therapeutic targets that work to reduce inflammation and subsequently reduce flares. This study explores existing therapeutic agents for atopic dermatitis as well as newer therapies such as biologics and small molecules, drawing upon each agent’s mechanism of action, relevant landmark clinical trials, efficacy, and safety profile. Current therapies include emollients, corticosteroids, cyclosporine A, calcineurin inhibitors, phototherapy, and methotrexate. Biologics described include dupilumab, tralokinumab, lebrikizumab, nemolizumab, and rocatinlimab. Small molecules inhibitors include Janus kinase inhibitors, phosphodiesterase 4 inhibitors, transient receptor potential vanilloid subfamily V member 1 antagonist, and aryl hydrocarbon receptor antagonist.

Item Metadata

Title
Biologic and Small Molecule Therapy in Atopic Dermatitis
Creator
Shergill, Mahek; Bajwa, Barinder; Yilmaz, Orhan; Tailor, Karishma; Bouadi, Naila; Mukovozov, Ilya
Publisher
Multidisciplinary Digital Publishing Institute
Date Issued
2024-08-13
Description
Atopic dermatitis is a chronic inflammatory dermatosis characterized by pruritic, scaly, erythematous lesions. Its incidence varies but is estimated to be approximately 20% in children and between 7 and 14% in adults, with variation amongst countries. It is a multifactorial condition, with a complex interplay between genetic, immunological, and environmental factors. Research into the inflammatory response has identified new therapeutic targets that work to reduce inflammation and subsequently reduce flares. This study explores existing therapeutic agents for atopic dermatitis as well as newer therapies such as biologics and small molecules, drawing upon each agent’s mechanism of action, relevant landmark clinical trials, efficacy, and safety profile. Current therapies include emollients, corticosteroids, cyclosporine A, calcineurin inhibitors, phototherapy, and methotrexate. Biologics described include dupilumab, tralokinumab, lebrikizumab, nemolizumab, and rocatinlimab. Small molecules inhibitors include Janus kinase inhibitors, phosphodiesterase 4 inhibitors, transient receptor potential vanilloid subfamily V member 1 antagonist, and aryl hydrocarbon receptor antagonist.
Subject
AD; Janus kinase inhibitors; JAK1; JAK2; JAK3; TYK2; dupilumab
Genre
Article
Type
Text
Language
eng
Date Available
2024-09-13
Provider
Vancouver : University of British Columbia Library
Rights
CC BY 4.0
DOI
10.14288/1.0445388
URI
http://hdl.handle.net/2429/89240
Affiliation
Medicine, Faculty of; Non UBC
Citation
Biomedicines 12 (8): 1841 (2024)
Publisher DOI
10.3390/biomedicines12081841
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
https://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

CC BY 4.0